sever
cap
defin
clinic
syndrom
develop
patient
pneumonia
requir
hospit
ward
intens
care
unit
million
hospit
annual
owe
cap
unit
state
cost
approxim
billion
dollar
per
year
approxim
hospit
patient
requir
intens
care
unit
admiss
hospit
patient
cap
risk
signific
mortal
depend
sever
ill
sever
studi
report
mortal
rate
approxim
hospit
ward
patient
rate
patient
requir
intens
care
unit
admiss
metaanalysi
publish
clinic
studi
evalu
shortterm
mortal
hospit
cap
patient
report
mortal
rate
ambulatori
ward
hospit
patient
mortal
rate
patient
treat
intens
care
unit
import
determin
hospit
assess
sever
cap
patient
chronic
comorbid
condit
prior
antibiot
use
prior
antibiot
use
defin
cap
clinic
practic
guidelin
use
antibiot
regimen
past
month
use
associ
increas
risk
morbid
mortal
common
comorbid
ill
chronic
obstruct
pulmonari
diseas
present
mani
half
patient
follow
alcohol
chronic
heart
diseas
diabet
see
front
matter
elsevi
inc
right
reserv
chestmedtheclinicscom
mellitu
comorbid
associ
condit
includ
renal
failur
neurolog
diseas
malnutrit
hepat
diseas
bacteremia
smoke
histori
gross
aspir
approxim
one
third
patient
cap
previous
healthi
elderli
nurs
home
patient
signific
risk
cap
high
mortal
rate
although
expert
consid
pneumonia
occur
nurs
home
patient
hospitalacquir
pneumonia
owe
similar
etiolog
pathogen
main
caus
death
patient
sever
cap
includ
refractori
hypoxemia
refractori
shock
pneumoniarel
complic
predominantli
multiorgan
failur
mortensen
et
al
evalu
caus
death
time
risk
factor
associ
pneumoniarel
pneumoniaunrel
mortal
patient
cap
within
day
present
pneumoniarel
death
time
like
occur
within
day
present
compar
pneumoniaunrel
mortal
prognosi
beyond
day
influenc
patient
age
sex
signific
comorbid
condit
sever
assess
criteria
hospit
intens
care
unit
admiss
one
critic
decis
physician
treat
patient
cap
whether
hospit
patient
ward
intens
care
unit
servic
decis
usual
made
outpati
offic
emerg
depart
implic
antibiot
class
select
rout
durat
therapi
sever
studi
develop
predict
rule
determin
site
care
patient
cap
base
sever
ill
fine
colleagu
develop
pneumoniaspecif
sever
ill
psi
score
part
pneumonia
patient
outcom
research
team
studi
port
primari
goal
psi
identifi
lowrisk
patient
might
manag
safe
home
paramet
includ
three
demograph
variabl
five
comorbid
condit
five
physic
examin
find
seven
laboratoryimag
result
variabl
present
point
ad
score
final
score
divid
five
risk
class
patient
risk
class
iii
low
mortal
risk
rate
less
manag
outpati
patient
risk
classif
iv
mortal
rate
class
v
patient
mortal
rate
studi
suggest
patient
class
iv
v
might
requir
hospit
followup
studi
investig
suggest
threestep
process
decid
initi
site
cap
treatment
base
assess
preexist
condit
compromis
safeti
home
care
calcul
psi
score
clinic
judgment
evalu
safeti
psi
marri
et
al
conduct
random
control
studi
use
critic
pathway
manag
pneumonia
nine
hospit
critic
pathway
group
compar
hospit
convent
manag
group
canadian
teach
commun
hospit
psi
score
use
assist
site
care
decis
implement
critic
pathway
includ
psi
score
result
reduc
use
institut
resourc
fewer
bed
day
per
patient
manag
decreas
admiss
lowrisk
patient
differ
rate
acut
complic
readmiss
mortal
consensu
regard
accept
criteria
definit
sever
cap
patient
requir
intens
care
unit
admiss
set
seven
clinic
criteria
recommend
at
guidelin
followup
studi
ewig
et
al
suggest
modifi
at
criteria
set
defin
sever
cap
investig
includ
presenc
two
three
minor
criteria
pao
fio
ratio
bilater
pneumonia
multilobar
infiltr
systol
blood
pressur
mm
hg
one
two
major
criteria
need
mechan
ventil
septic
shock
need
vasopressor
hour
criteria
adopt
recent
at
guidelin
patient
sever
cap
cordero
colleagu
valid
at
sever
criteria
hivinfect
patient
british
thorac
societi
bt
publish
rule
identifi
sever
ill
patient
base
three
criteriaan
increas
respiratori
rate
increas
blood
urea
nitrogen
decreas
blood
pressureand
later
convert
rule
includ
four
criteria
ad
mental
statu
chang
subsequ
new
predict
rule
studi
base
modifi
bt
rule
rule
call
curb
confus
blood
urea
nitrogen
mmoll
respiratori
rate
low
systol
mm
hg
diastol
mm
hg
blood
pressur
age
greater
year
independ
associ
poor
outcom
ad
creat
sixlevel
score
similar
score
blood
urea
nitrogen
omit
creat
appli
rule
outpati
set
score
fivelevel
score
correl
mortal
allow
identif
patient
low
intermedi
high
risk
death
angu
et
al
compar
differ
set
criteria
predictor
use
pneumonia
port
databas
found
current
recommend
criteria
carri
modest
valu
level
reliabl
individu
score
system
evalu
includ
initi
at
publish
revisit
bt
psi
score
recent
at
criteria
rule
publish
best
discrimin
intens
care
unit
admiss
need
mechan
ventil
area
receiveroper
characterist
curv
respect
none
predict
rule
particularli
good
psi
score
best
predictor
medic
complic
death
area
receiveroper
characterist
curv
respect
sever
assess
criteria
use
help
physician
identifi
patient
may
need
hospit
intens
care
unit
admiss
meant
remov
physician
clinic
judgment
decisionmak
process
treatment
guidelin
develop
sever
profession
organ
standard
therapi
cap
includ
patient
sever
cap
publish
practic
guidelin
reflect
evolut
expert
opinion
chang
resist
pattern
avail
new
clinic
data
regard
treatment
diagnosi
cap
immunocompet
adult
guidelin
support
concept
treatment
hospit
patient
cap
focus
possibl
associ
etiolog
agent
earli
aggress
therapeut
approach
main
intervent
decreas
mortal
patient
cap
empir
treatment
combin
antimicrobi
therapi
initi
prefer
within
first
hour
present
least
first
hour
admiss
earlier
administr
antibiot
associ
improv
surviv
current
consid
import
paramet
assess
process
care
diseas
houck
et
al
report
antibiot
administr
within
hour
arriv
associ
decreas
mortal
length
stay
among
random
sampl
older
inpati
cap
receiv
antibiot
outpati
empir
therapi
direct
streptococcu
pneumonia
haemophilu
influenza
gramneg
bacilli
betalactam
medic
new
respiratori
fluoroquinolon
legionella
spp
atyp
pathogen
cover
macrolid
fluoroquinolon
mix
infect
typic
atyp
pathogen
occur
approxim
case
alway
consid
ensur
patient
treat
appropri
empir
antimicrobi
therapi
case
infect
pathogen
identifi
direct
therapi
employ
clinic
seri
approxim
patient
cap
pathogen
identifi
failur
identifi
pathogen
associ
wors
outcom
empir
regimen
cover
pneumonia
atyp
pathogen
common
empir
antibiot
regimen
suggest
patient
cap
receiv
ward
servic
includ
thirdgener
cephalosporin
combin
macrolid
fluoroquinolon
tabl
retrospect
record
review
medicar
inpati
age
year
older
gleason
et
al
show
initi
treatment
cap
secondgener
cephalosporin
plu
macrolid
non
antipseudomon
thirdgener
cephalosporin
plu
macrolid
fluoroquinolon
alon
independ
associ
lower
mortal
patient
psi
class
iv
v
burgess
lewi
perform
retrospect
evalu
hospit
intens
care
unit
patient
cap
conclud
addit
macrolid
non
antipseudomon
thirdgener
cephalosporin
initi
therapi
treatment
cap
may
necessari
nevertheless
report
suggest
use
combin
regimen
macrolid
fluoroquinolon
alon
associ
better
outcom
use
betalactam
alon
oosterheert
et
al
publish
systemat
review
use
empir
therapi
hospit
patient
cap
review
eight
nonexperiment
cohort
studi
one
prospect
studi
random
control
trial
six
studi
demonstr
signific
reduct
mortal
use
fluoroquinolon
monotherapi
combin
betalactam
macrolid
one
studi
show
reduct
hospit
length
stay
suggest
benefit
macrolid
might
occur
owe
coverag
unrecogn
atyp
pathogen
possibl
antiinflammatori
effect
coverag
resist
pathogen
clinic
practic
guidelin
suggest
patient
sever
cap
admit
intens
care
unit
stratifi
whether
risk
pseudomona
spp
infect
patient
risk
factor
pseudomona
infect
treatment
alway
includ
two
antibioticson
cover
pneumococcu
includ
drugresist
isol
anoth
cover
atyp
pathogen
especi
legionella
spp
tabl
patient
risk
factor
p
aeruginosa
admit
intens
care
unit
requir
specif
attent
receiv
appropri
antipseudomon
agent
see
tabl
author
colleagu
perform
systemat
review
determin
benefit
use
combin
therapi
versu
monotherapi
patient
sever
cap
admit
intens
care
unit
four
studi
met
predefin
inclus
criteria
one
random
control
trial
three
cohort
studi
method
use
determin
sever
ill
vari
two
studi
one
random
control
trial
one
cohort
studi
use
at
sever
criteria
two
cohort
studi
use
psi
score
random
control
trial
much
lower
mortal
rate
studi
use
unusu
antimicrobi
combin
therapi
betalactam
versu
teicoplanin
plu
ciprofloxacin
one
recommend
regimen
put
forth
differ
clinic
guidelin
tabl
empir
antimicrobi
regimen
treat
sever
communityacquir
pneumonia
intens
care
unit
conclud
limit
number
studi
antimicrobi
therapi
patient
sever
cap
heterogen
contain
limit
inform
compar
differ
mortal
patient
sever
cap
treat
combin
therapi
versu
monotherapi
pneumonia
isol
mani
onethird
ward
intens
care
unit
patient
sever
studi
publish
moroney
et
al
kalin
et
al
metlay
et
al
evalu
clinic
outcom
patient
bacterem
pneumococc
pneumonia
antimicrobi
resist
bacterem
pneumonia
show
contribut
mortal
requir
intens
care
unit
admiss
may
associ
increas
risk
advers
outcom
suppur
complic
infect
eg
empyema
water
et
al
found
singleeffect
drug
therapi
sever
bacterem
pneumococc
pneumonia
associ
greater
risk
death
dualeffect
therapi
two
studi
suggest
benefit
macrolid
ad
betalactam
therapi
patient
bacterem
pneumococc
pneumonia
ad
macrolid
betalactambas
initi
antibiot
regimen
independ
predictor
inhospit
mortal
concern
regard
drugresist
pneumonia
therapi
discuss
elsewher
issu
h
influenza
therapi
depend
product
betalactamas
enzym
present
amoxicillin
appropri
microbi
product
betalactamas
requir
use
thirdgener
cephalosporin
betalactambetalactamas
inhibitor
fluoroquinolon
altern
agent
includ
newer
macrolid
clarithromycin
azithromycin
doxycyclin
enterobacteria
manag
thirdgener
cephalosporin
betalactambetalactamas
inhibitor
fluoroquinolon
past
sever
year
chang
clinic
present
staphylococcu
aureu
emerg
especi
emerg
communityacquir
strain
methicillin
resist
microorgan
treat
vancomycin
linezolid
altern
prefer
antimicrobi
agent
atyp
microorgan
chlamydiophilia
pneumonia
mycoplasma
pneumonia
legionella
spp
fluoroquinolon
macrolid
doxycyclin
macrolid
tetracyclin
prefer
infect
caus
coxiella
burnetii
chlamydia
psittaci
viral
pneumonia
result
commun
outbreak
influenza
respiratori
syncyti
viru
parainfluenza
life
threaten
elderli
immunocompromis
patient
influenza
pneumonia
may
complic
direct
involv
lung
parenchyma
secondari
bacteri
infect
caus
pneumonia
aureu
h
influenza
gramneg
pathogen
amantadin
rimantadin
use
patient
influenza
newer
agent
oseltamivir
zanamivir
cover
influenza
b
patient
infect
sin
nombr
hantaviru
may
present
acut
respiratori
failur
requir
intens
care
unit
admiss
mechan
ventil
condit
associ
high
mortal
rate
support
therapi
avail
recent
two
pathogen
describ
associ
sever
cap
sar
coronaviru
metapneumoviru
p
aeruginosa
report
patient
sever
cap
specif
risk
factor
chronic
prolong
use
broadspectrum
antibiot
therapi
bronchiectasi
malnutrit
hiv
immunosuppress
specif
treatment
includ
intraven
antipseudomon
betalactambetalactamas
inhibitor
plu
intraven
aminoglycosid
intraven
ciprofloxacin
plu
intraven
macrolid
aminoglycosid
use
use
ciprofloxacin
see
tabl
organ
describ
possibl
pathogen
includ
endem
fungi
mycobacterium
tuberculosi
pneumocysti
jiroveci
formerli
p
carinii
pneumonia
deserv
mention
herein
although
usual
exclud
cap
guidelin
pathogen
suspect
immunocompromis
patient
certain
endem
area
requir
specif
antifung
antitubercul
therapi
aspir
pneumonia
owe
anaerob
infect
treat
carbapenem
clindamycin
betalactambetalactamas
inhibitor
gener
durat
therapi
patient
sever
cap
day
patient
atyp
pathogen
legionella
spp
receiv
longer
treatment
day
sever
studi
report
use
critic
pathway
improv
treatment
patient
cap
includ
sever
diseas
antimicrobi
treatment
failur
nonresolv
pneumonia
usual
underestim
discuss
elsewher
issu
common
caus
includ
microbi
resist
initi
antimicrobi
regimen
suppur
complic
presenc
nosocomi
pneumonia
initi
clinic
improv
hospit
patient
switch
intraven
oral
antibiot
therapi
maintain
similar
antimicrobi
coverag
tissu
concentr
parenter
form
criteria
determin
patient
make
transit
oral
antibiot
includ
abil
toler
antibiot
mouth
function
gastrointestin
tract
stabl
blood
pressur
chang
toward
normal
white
blood
cell
count
improv
symptom
cough
dyspnea
fever
metaanalysi
rhew
et
al
evalu
earli
intraven
oral
convers
discharg
strategi
patient
cap
find
suggest
intervent
associ
signific
safe
reduct
mean
length
hospit
stay
sever
qualiti
indic
alreadi
mention
includ
earli
administr
antibiot
appropri
antibiot
use
follow
clinic
practic
guidelin
use
critic
pathway
switch
oral
therapi
earli
discharg
show
improv
clinic
outcom
cap
addit
measur
direct
prevent
vaccin
pneumococc
influenza
infect
counsel
quit
smoke
patient
risk
may
help
decreas
incid
cap
import
process
care
includ
collect
blood
cultur
antibiot
administr
first
hour
test
legionella
infect
intens
care
unit
patient
evalu
oxygen
measur
blood
gase
puls
oximetri
cap
lifethreaten
condit
requir
hospit
patient
intens
care
unit
admiss
underli
comorbid
condit
commonli
chronic
obstruct
pulmonari
diseas
alcohol
chronic
heart
diseas
diabet
mellitu
frequent
seen
group
patient
common
etiolog
agent
found
cap
pneumonia
legionella
spp
gramneg
rod
especi
klebsiella
pneumonia
p
aeruginosa
intens
care
unit
patient
risk
factor
eg
bronchiectasi
although
half
case
lack
specif
etiolog
diagnosi
earli
rapid
initi
empir
antimicrobi
therapi
concord
recommend
clinic
practic
guidelin
base
epidemiolog
approach
possibl
etiolog
agent
sever
ill
initi
antimicrobi
therapi
consist
antipneumococc
fluoroquinolon
alon
intraven
betalactam
antibiot
plu
macrolid
hospit
patient
intraven
betalactam
antibiot
plu
macrolid
antipneumococc
fluoroquinolon
provid
intens
care
unit
patient
without
risk
pseudomona
antipseudomon
therapi
indic
patient
risk
factor
pseudomona
admit
intens
care
unit
modif
initi
regimen
consid
specif
pathogen
identifi
optim
manag
patient
hospit
cap
requir
research
reevalu
new
data
avail
